Breo Ellipta® 200/25 mcg (fluticasone furoate and vilanterol) is a prescription inhalation powder used for the long-term maintenance treatment of chronic obstructive pulmonary disease (COPD) and asthma. This combination inhaler contains fluticasone furoate, a corticosteroid that reduces airway inflammation, and vilanterol, a long-acting beta-agonist (LABA) that helps to open the airways by relaxing the muscles. This dual-action formula helps to reduce the frequency of COPD and asthma symptoms, improve lung function, and prevent flare-ups.

Features:

• Dual-Action Combination: Breo Ellipta® 200/25 mcg combines the powerful effects of fluticasone furoate (a corticosteroid) and vilanterol (a LABA) for the treatment of COPD and asthma.

• FDA-Approved: Approved by the FDA for the maintenance treatment of COPD and asthma in adults and adolescents aged 12 years and older.

• Long-Lasting Relief: Provides 24-hour relief with just one inhalation per day, helping patients manage their symptoms and reduce flare-ups throughout the day.

• Improves Lung Function: Clinical studies have demonstrated that Breo Ellipta® significantly improves lung function, reduces exacerbations, and helps control daily symptoms like wheezing, coughing, and shortness of breath.